The capacity for sulphation of phenols appears to be impaired in the colonic mucosa of patients with ulcerative colitis. The aim of the present study was to investigate the systemic capacity for sulphation of phenols in patients with ulcerative colitis assessed by the metabolic clearances of paracetamol to the sulphate, glucuronide and glutathione derived metabolites. Methods Ten patients with ulcerative colitis and 10 control subjects received a single oral dose of paracetamol (1 g ). Venous blood samples were collected frequently for pharmacokinetic determinations (one compartment model). Urine was collected for 24 h. Plasma samples were analysed for parent drug and urine samples for parent drug and metabolites by h.p.l.c. Partial metabolic clearances were calculated as the fractional urinary recovery of each conjugate multiplied by the apparent oral clearance of paracetamol. Results The apparent oral clearance of paracetamol and the partial clearances of its metabolites were not significantly different between the two study groups. Median value and the corresponding 25th and 75th percentiles for the clearance of the sulphate metabolites were 93.6 (82.5-138.8) ml kg −1 h −1 and 77.4 (75.5-99.1), patients with ulcerative colitis and control subjects, respectively. Conclusions These results do not indicate a general impairment of the systemic capacity for sulphation of paracetamol in patients with ulcerative colitis.
Introduction finding makes it relevant to consider an impaired sulphation capacity of phenols of the colonic mucosa in ulcerative Ulcerative colitis is a chronic inflammatory disease of unknown origin. Periods of remission alternate with periods colitis to be one possible pathogenetic prerequisite for active disease. This is further supported by the observation, that of exacerbation, the latter often requiring intensive antiinflammatory drug treatment with 5-ASA preparations and relapses of ulcerative colitis have been associated with preceding intake of paracetamol [7] . Whether the impaired steroids or in severe cases even colectomy. The aetiology of these relapses is unknown, and exogenous as well as sulphoconjugation of paracetamol is restricted to the abnormal colonic mucosa or is constitutional in patients endogenous factors may play a role.
The colonic lumen contains considerable amounts of with ulcerative colitis remains to be investigated. In the present study the systemic sulphation of paracetamol was phenols which are partly derived from bacterial fermentation of protein [1] , and partly from xenobiotics and their investigated in patients with ulcerative colitis and controls. metabolic products. Some of these phenols may have adverse effects in the body. Paracetamol is one xenobiotic phenol Methods well known to possess toxicological potential, and other phenols have been shown to be tumour promoters in skin Ten outpatients with established ulcerative colitis, two men cancer [2] , and have also been implicated in the development and eight women, and 10 healthy control subjects, four men of both bladder and bowel cancer [3, 4] . Sulphation is a and six women, participated in the study after giving major conjugative pathway for detoxification and inactiinformed consent. The study was approved by the ethics vation of various xenobiotics and endogenous compounds committee of Copenhagen County. The median age and such as phenols and hormones. It takes place in most tissues body weight of patients and controls were 52.5 (45.0-63.0) although predominantly in the liver. Recently, ) and 75.0 sulphation of phenols by the colonic mucosa has been (66.0-80) kg, respectively. The diagnosis of the ulcerative shown in quiescent and active ulcerative colitis [5] . In this colitis patients was based on clinical, histological, and study paracetamol was used as model compound being a radiological or endoscopic criteria. None of the patients had phenol and a drug mainly dependent on metabolism and undergone bowel surgery. The disease in all patients was considered inactive. Two patients were treated with topical the patients or control subjects had a daily intake of alcohol. estimated by linear regression of the terminal log drug concentration values (k e ). On the study day and the preceding day all refrained from taking any drugs except the prescribed medication.
Following an overnight fast each subject received a single t 1/2 = ln 2 k e oral dose of 1 g paracetamol (two 500 mg tablets paracetamol with 100 ml water). A light meal was allowed 2 h after the The renal clearance of paracetamol and the partial clearance dose. Venous blood samples were taken at 0 ( predose) and to the glucuronide and sulphate metabolites were calculated 1, 2, 3, 4 and 6 h after dosage via an indwelling cannula.
from the apparent oral clearance of paracetamol multiplied Plasma was separated after centrifugation of blood samples by the fraction of the dose excreted in urine as the and stored at −20°C. Urine was collected for 24 h after metabolite in 24 h. Partial clearance down the glutathione the administration of paracetamol, and aliquots of urine pathway was calculated likewise from the fraction of the were stored at −20°C. Plasma samples were analysed for sulphur containing paracetamol metabolites (cysteineparent drug and urine samples for parent drug and metabolites P+mercapturate-P) recovered in urine multiplied by the by h.p.l.c [8] . Glucuronide, sulphate and glutathione derived apparent oral clearance of paracetamol. metabolites in urine were assayed in duplicate, and coefficients of variation were 2.5%, 3.1% and 6.2%, Statistics respectively.
Statistical comparisons were made using the Mann-Whitney rank sum test for unpaired observations taking the critical Pharmacokinetic analysis value of P as 0.05. Values are expressed as median and 25th-75th percentiles. The study was designed with sufficient The area under the plasma drug concentration vs time power to detect a 40% difference in the total clearance of profile (AUC) was calculated according to the linear paracetamol and the partial clearances of its metabolites. The trapezoidal rule up to the end of sampling using a computer EXCEL statistical program (Microsoft inc.) was used for program (EXCEL, Microsoft inc.), and adding the remaining all analyses. area which was extrapolated to infinity using the terminal log drug concentration-time slope. The fraction of the AUC extrapolated was on average 16.2%.
Results

In the absence of an exact measurement of bioavailability
Patients with ulcerative colitis were significantly older than in this study the systemic clearance of paracetamol could the control subjects, but there was no difference in median not be assessed accurately. However, paracetamol is normally weight between the two groups. The pharmacokinetic well absorbed, and the total urinary recovery of paracetamol parameters for paracetamol disposition, and data on the and its conjugates is #85-90% of the dose [9, 10] . Thus, urinary excretion and the partial metabolic clearances in the systemic clearance is almost equal to the apparent oral patients and controls are shown in Table 1 . The median clearance (CL po ) which was estimated from:
value of the apparent oral clearance of paracetamol in patients with ulcerative colitis did not differ significantly CL po = Dose AUCΩBodyweight . from the controls. In addition, there was no significant difference in the urinary excretion of any metabolite, expressed either as a percentage of the dose or clearance to The plasma elimination half-life (t 1/2 ) of paracetamol was Paracetamol 3 (2-3) 3 (2-4) −1.4 -0.9
Clearance to metabolite (ml h − 1 kg Short report the metabolite. The terminal plasma half-life differed [7] . Yet another possible mechanism could involve a local injurious effect on the colonic mucosa of non absorbed significantly between the two groups ( P<0.05). The median recovery expressed as the percentage of the dose recovered paracetamol, considering that the local detoxification of paracetamol appears to be impaired in these patients [5] . in the urine in 24 h was 89.6% in patients and 64.0% in controls, ( P >0.05) .
Despite the relatively few participants in the present study, the fact that patients had partial clearances to all metabolites of paracetamol comparable with controls make clinically Discussion relevant metabolic changes of the sulphation pathway in patients with ulcerative colitis very unlikely. Since the colon The paper by Ramakrishna et al. [5] raised theoretically an important question whether the demonstrated low sulphation is exposed to xenobiotic phenols ingested with food and locally from bacterial fermentation of proteins [1] , further capacity of the colonic mucosa is a local or constitutional phenomenon. Other disease states have been associated with study of the mechanism of the low sulphation capacity of the colonic mucosa is warranted. These compounds may a lower urinary excretion of the sulphate conjugate of paracetamol [11] [12] [13] , and low levels of the enzyme phenpossess toxicological potential and may be incriminated as one possible explanation to relapses in ulcerative colitis. ol-sulphotransferase, reduced amounts of inorganic sulphate or decreased formation of 3∞-phosphoadenosine-5∞-
The technical assistance of Jytte Purtoft is greatly appreciated. phosphosulphate (PAPS) have been proposed as possible explanations in these conditions. The present study gives no indication of a systemic impairment of the metabolism of oral administered paracetamol to the sulphate metabolite in References patients with ulcerative colitis. In fact the fractional urinary elimination half-life appeared to be significantly lower in
